Can the inflammatory bowel disease biologics registry lead to improved quality of care?

Alrubaiy, Laith; Rikaby, Ibtihal; Hutchings, Hayley; Williams, John

doi:10.1016/j.jtumed.2015.02.008

Cited by 2 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can be hypothesized that since recurrence interval of the perianal abscess was 14 days, initiation of the reinfection process leads to higher pain severity in this patients two weeks after intervention. In the literature, diabetes mellitus, hypertension and Crohn's diseases have been considered as risk factor for development of the perianal fistula, however, our results showed no significant correlation between DM and perianal abscess recurrence (11,26,27). Whereas, in a survey, Adamo et al discussed the risk factors for readmission after initial intervention in patients underwent perianal abscess treatment and showed that although age and gender was not in association with higher rate of the readmission in these patients, history of Crohn's disease had significant impact on the risk for the readmission (7).…”

Section: Discussioncontrasting

confidence: 54%

Factors Predisposing Perianal Abscess Recurrence in Patient Underwent Incision and Drainage: A Retrospective Study

Rezaee¹,

Ashodari

Rashno

et al. 2019

EIJMHS

View full text Add to dashboard Cite

Introduction: The perianal abscess recurrence is a common complication after the incision and drainage (I&D) intervention. We aimed to study the effect of other perianal diseases on treatment outcomes and recurrence of the perianal abscess in patients who undergone incision and drainage. Methods: During a retrospective study, in a two-year period, patients with perianal abscess underwent incision and drainage (I&D) enrolled study. Patient’s demographic features and abscess characteristics including location of the abscess, abscess superficial or deep position in pelvis, presence of the concomitant fistula and in hospital admission features such as length of hospital admission and postoperative pain severity recorded. Results: Perianal abscess recurrence was significantly higher in patients suffering Fischer lesion and fistula compared to patients without recurrence (P= 0.032 and P< 0.001). There was no significant correlation between abscess recurrence and postoperative complications, however, perianal fistula recurrence was significantly higher in patients who had previous history of the perianal fistula (P= 0.001). Patients with Fischer lesion had 25.35 times higher odds to exhibit abscess recurrence compared patients without Fischer. Previous history of the perianal fistula was associated with an increased likelihood of exhibiting perianal abscess recurrence up to 42.44 times higher odds. Conclusion: Patients with perianal abscess candidate to undergo incision and drainage suffering preoperative perianal fistula and Fischer lesion are at higher risk for development of the abscess recurrence.

show abstract

Section: Discussioncontrasting

confidence: 54%

Factors Predisposing Perianal Abscess Recurrence in Patient Underwent Incision and Drainage: A Retrospective Study

Rezaee¹,

Ashodari

Rashno

et al. 2019

EIJMHS

View full text Add to dashboard Cite

show abstract

Biosimilar medicines and patient registries – expectations, limitations, and opportunities

Sutka

Pecova

2017

Acta Medica Martiniana

View full text Add to dashboard Cite

Introduction: Biology therapies in a various medical specializations and for a broad spectrum of indications were launched during last two decades. As a new in class the therapies were obliged to provide additional data re gar ding efficacy and safety after their real medical practice integration. Patient registries, databases collecting various patient data, were introduced to grant data on the treatment effectiveness, safety, and long-term on treatment survival. Satisfactory treatment effect and acceptable safety profile were confirmed after couple of years of careful observation. However, the benefits were usually offered at much higher treatment costs compared to the standard therapies. Biologically similar drugs, so-called biosimilars (B.S), are being launched after original molecule patent protection expiry during recent years. They were expected as an ideal solution to avoid distinct impact on the medical budget: comparable effect for less money. The unsubstantiated doubts about biosimilar efficacy and safety were the reason of the late launch in many markets. Since biosimilars are considered as new therapy entities, the cautiousness to certain extent should be required. Information gained from post-marketing observations and patient registries over several years, confirmed the biosimilar product comparable quality. Healthcare budget savings could secure easier therapy access for more new patients.

show abstract

Can the inflammatory bowel disease biologics registry lead to improved quality of care?

Cited by 2 publications

References 12 publications

Factors Predisposing Perianal Abscess Recurrence in Patient Underwent Incision and Drainage: A Retrospective Study

Factors Predisposing Perianal Abscess Recurrence in Patient Underwent Incision and Drainage: A Retrospective Study

Biosimilar medicines and patient registries – expectations, limitations, and opportunities

Contact Info

Product

Resources

About